Is It Possible to Target HER2 Using Affibody Receptor Radionuclide Therapy?-Reference-Cited by-同舟云学术

Is It Possible to Target HER2 Using Affibody Receptor Radionuclide Therapy?

Published:2024 Issue: Volume: Page:375-380
ISSN:
Container-title:Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum
language:en
Short-container-title:

Author:

Zhu Hua,Guo Xiaoyi,Meng Xiangxi,Yang Zhi

Abstract

AbstractHuman epidermal receptor type 2 (HER2; also known as ErbB2) is an idea target for target therapy. HER2-targeted treatments with trastuzumab and its derivates or analogues can improve the overall survival of patients with HER2-overexpression tumors. This chapter describes the construction and clinical translational study of 64Cu-NOTA-Trastuzumab, 124I-Trastuzumab, and 68Ga-HER2 affibody tracer. Inspired by recently most popular peptide receptor radionuclide therapy with lutetium-177 dotatate (177Lu-DOTATATE) for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and 177Lu-PSMA-617 for metastatic castration resistant prostate cancer therapy (mCRPC), the establishment of affibody receptor radionuclide therapy (ARRT) has the potential to provide an alternative treatment option for future HER2 positive resistant patients.

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-031-33533-4_38

Reference4 articles.

1. Guo X, Zhu H, Zhou N, Chen Z, Liu T, Liu F, Xiaoxia X, Jin H, Shen L, Gao J, Yang Z. Non-invasive detection of HER2 expression in gastric cancer by 64Cu-NOTA-trastuzumab in PDX mouse model and in patients. Mol Pharm. 2018;15(11):5174–82.

2. Guo X, Zhou N, Chen Z, Liu T, Xiaoxia X, Lei X, Shen L, Gao J, Yang Z, Zhu H. Construction of 124I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients. Gastric Cancer. 2020;23:614. https://doi.org/10.1007/s10120-019-01035-6.

3. Zhou N, Guo X, Yang M, Zhu H, Yang Z. 68Ga-ZHER2 PET/CT reveals HER2-positive metastatic gastric cancer with better image quality than 18F-FDG. Clin Nucl Med. 2020;45:e101. https://doi.org/10.1097/RLU.0000000000002859.

4. Zhou N, Liu C, Guo X, Yuping X, Gong J, Qi C, Zhang X, Yang M, Zhu H, Shen L, Yang Z. 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. Eur J Nucl Med Mol Imaging. 2020;48:161. https://doi.org/10.1007/s00259-020-04898-5.